Objective To compare the safety and effectiveness between robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC) and open radical cystectomy (ORC). Methods We conducted this systematic review and meta-analysis of the primary outcomes of interest according to the PRISMA and AMSTAR Guidelines. Five databases were systematically searched, including Medline, PubMed, Cochrane Library, Scopus, and Web of Science. The search timeframe was set from database creation to February 2026. Results There were 30 studies including 8857 patients. Compared with ORC, iRARC was superior in terms of estimated blood loss [WMD=-523.18, 95% CI (-622.68, -423.68), P < 0.01], length of stay [WMD=-2.30, 95% CI (-3.27, -1.33), P < 0.01], lymph nodes removed [WMD = 2.39, 95% CI (0.16, 4.62), P < 0.05], transfusion [OR = 0.15, 95% CI (0.08, 0.29), P < 0.01], positive surgical margin [OR = 0.73, 95% CI (0.55, 0.96), P < 0.05], postoperative complications [OR = 0.59, 95% CI (0.37, 0.95), P < 0.05], Clavien-Dindo > II complications [OR = 0.66, 95% CI (0.47, 0.94), P < 0.05], and intraoperative complications [OR = 0.51, 95% CI (0.26, 0.97), P < 0.05], but it had a longer operative time [WMD = 66.11, 95% CI (45.31, 86.90), P < 0.01]. The two surgical groups were comparable in terms of solid food intake time (p = 0.29), bowel obstruction (p = 0.36), and Clavien-Dindo I-II complications (p = 0.34). Postoperative long-term follow-up results showed that iRARC was superior in terms of 30-day complications [OR = 0.58, 95% CI (0.38, 0.88), P < 0.05], 90-day complications [OR = 0.67, 95% CI (0.58, 0.78), P < 0.01], 30-day Clavien-Dindo > II complications [OR = 0.66, 95% CI (0.52, 0.84), P < 0.05], 90-day Clavien-Dindo > II complications [OR = 0.77, 95% CI (0.63, 0.94), P < 0.01], 5-year cancer-specific survival [CSS HR = 0.71, 95% CI (0.51, 0.98), P < 0.05], and 5-year overall survival [OS HR = 0.73, 95% CI (0.60, 0.87), P < 0.01], but it had a higher incidence of ureteroenteric stricture [UES OR = 1.57, 95% CI (1.18, 2.09), P < 0.01]. The two surgical groups were comparable in terms of 30-day Clavien-Dindo I-II complications (p = 0.28), 90-day Clavien-Dindo I-II complications (p = 0.99), 30-day readmission (p = 0.68), 90-day readmission (p = 0.51), 90-day death (p = 0.37), recurrence (p = 0.18), 3-year CSS (p = 0.88), and 3-year OS (p = 0.19). Conclusion Compared with ORC, iRARC was associated with improved perioperative outcomes, but attention should be paid to the monitoring and management of postoperative UES. Although improved 5-year OS and CSS were observed, these findings should be interpreted with caution because most of the available evidence was derived from observational studies and may have been influenced by residual confounding. Further large-scale, high-quality randomized controlled trials are needed to validate these findings.

Intra-corporeal robot-assisted versus open radical cystectomy: a meta-analysis

期刊论文
发表日期：

2026年7月29日

查看全文

Lijian Gan,
Jiyue Wu,
Zhen Li,
Huawei Cao,
Hao Wang,
Yuqing Li,
Zejia Sun,
Wei Wang

摘要

Objective

To compare the safety and effectiveness between robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC) and open radical cystectomy (ORC).

Methods

We conducted this systematic review and meta-analysis of the primary outcomes of interest according to the PRISMA and AMSTAR Guidelines. Five databases were systematically searched, including Medline, PubMed, Cochrane Library, Scopus, and Web of Science. The search timeframe was set from database creation to February 2026.

Results

There were 30 studies including 8857 patients. Compared with ORC, iRARC was superior in terms of estimated blood loss [WMD=-523.18, 95% CI (-622.68, -423.68), P < 0.01], length of stay [WMD=-2.30, 95% CI (-3.27, -1.33), P < 0.01], lymph nodes removed [WMD = 2.39, 95% CI (0.16, 4.62), P < 0.05], transfusion [OR = 0.15, 95% CI (0.08, 0.29), P < 0.01], positive surgical margin [OR = 0.73, 95% CI (0.55, 0.96), P < 0.05], postoperative complications [OR = 0.59, 95% CI (0.37, 0.95), P < 0.05], Clavien-Dindo > II complications [OR = 0.66, 95% CI (0.47, 0.94), P < 0.05], and intraoperative complications [OR = 0.51, 95% CI (0.26, 0.97), P < 0.05], but it had a longer operative time [WMD = 66.11, 95% CI (45.31, 86.90), P < 0.01]. The two surgical groups were comparable in terms of solid food intake time (p = 0.29), bowel obstruction (p = 0.36), and Clavien-Dindo I-II complications (p = 0.34). Postoperative long-term follow-up results showed that iRARC was superior in terms of 30-day complications [OR = 0.58, 95% CI (0.38, 0.88), P < 0.05], 90-day complications [OR = 0.67, 95% CI (0.58, 0.78), P < 0.01], 30-day Clavien-Dindo > II complications [OR = 0.66, 95% CI (0.52, 0.84), P < 0.05], 90-day Clavien-Dindo > II complications [OR = 0.77, 95% CI (0.63, 0.94), P < 0.01], 5-year cancer-specific survival [CSS HR = 0.71, 95% CI (0.51, 0.98), P < 0.05], and 5-year overall survival [OS HR = 0.73, 95% CI (0.60, 0.87), P < 0.01], but it had a higher incidence of ureteroenteric stricture [UES OR = 1.57, 95% CI (1.18, 2.09), P < 0.01]. The two surgical groups were comparable in terms of 30-day Clavien-Dindo I-II complications (p = 0.28), 90-day Clavien-Dindo I-II complications (p = 0.99), 30-day readmission (p = 0.68), 90-day readmission (p = 0.51), 90-day death (p = 0.37), recurrence (p = 0.18), 3-year CSS (p = 0.88), and 3-year OS (p = 0.19).

Conclusion

Compared with ORC, iRARC was associated with improved perioperative outcomes, but attention should be paid to the monitoring and management of postoperative UES. Although improved 5-year OS and CSS were observed, these findings should be interpreted with caution because most of the available evidence was derived from observational studies and may have been influenced by residual confounding. Further large-scale, high-quality randomized controlled trials are needed to validate these findings.